REPL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Replimune Group Inc (REPL) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant regulatory setbacks, negative sentiment from analysts, weak technical indicators, and poor financial performance. Given the lack of positive catalysts and the high uncertainty surrounding the company's future, it is advisable to avoid investing in this stock at this time.
The technical indicators for REPL are bearish. The MACD histogram is negative and contracting, RSI is neutral at 44.145, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 3.52 and support at 1.553, suggesting further downside potential.
NULL identified. There are no positive catalysts or events that could drive the stock price upward in the near term.
The FDA's second rejection of Replimune's RP1 drug has significantly impacted the company's market prospects. Analysts have downgraded the stock across the board, citing regulatory challenges and financial difficulties. Additionally, the company is under investigation for potential securities fraud, further damaging investor confidence.
Replimune's financial performance is weak. In Q3 2026, the company reported zero revenue and a net loss of $70.93 million, which, although improved by 6.92% YoY, still reflects a negative EPS of -0.77, down 2.53% YoY. Gross margin remains at 0, indicating no profitability.
Analysts have overwhelmingly downgraded the stock following the FDA's rejection of RP1. Price targets have been slashed to as low as $1-$4, with firms like Wedbush, Leerink, H.C. Wainwright, JPMorgan, and others expressing significant concerns about the company's future and regulatory hurdles.
